Page 7 - Polyphor Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-Adhoc: Polyphor AG: Polyphor to present full-year 2020 financial results on March 5 Polyphor to present full-year 2020 financial results on March 5 26-Feb-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, February 26, 2021 Polyphor to Present Full-Year 2020 Financial Results on March 5 Polyphor AG (SIX: POLN) announced today that it will publish its full-year financial results for 2020 on March 5 at 7:30am CET. Gökhan Batur (CEO) and Hernan Levett (CFO) will host ...

Share this article Share this article ResearchAndMarkets.com's offering. Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts.The publisher has looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics ...

News Category Global Banking & Finance Reviews Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event ALLSCHWIL, Switzerland, Jan. 05, 2021 — Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern...

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin December 22, 2020 01:30 ET | Source: Polyphor AG Polyphor AG Allschwil, SWITZERLAND Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Polyphor’s inhaled murepavadin is a novel class antibiotic that specifically targets Pseudomonas aerug...

(2) EQS Group-Ad-hoc: Polyphor AG / Key word(s): Study Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications 14-Dec-2020 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 14, 2020 Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications Polyphor AG (SIX: POLN) annou...